Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of α1-adrenoceptor function

Psychopharmacology

Volumn 199, Issue 1, 2008, Pages 15-27

  Nourian, Z ^a   Mow, T ^b   Muftic, D ^b   Burek, S ^b   Pedersen, M L ^b   Matz, J ^b   Mulvany, M J ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b H LUNDBECK A S   (Denmark)

Author keywords

1 Adrenoceptors; Antipsychotic drugs; Aorta; Rat; Small mesenteric artery; Tilt model

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1D ADRENERGIC RECEPTOR; ARIPIPRAZOLE; CLOZAPINE; DOMPERIDONE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PHENYLEPHRINE; PRAZOSIN; RISPERIDONE; SERTINDOLE; ZIPRASIDONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG POTENCY; MALE; NONHUMAN; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; RESISTANCE BLOOD VESSEL; WISTAR RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; AORTA; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPOTENSION, ORTHOSTATIC; MALE; MESENTERIC ARTERIES; PHENYLEPHRINE; PRAZOSIN; RATS; RECEPTORS, ADRENERGIC, ALPHA-1; VASOCONSTRICTION;

EID: 46149101425     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-007-1064-9     Document Type: Article

References (52)

1. Akiyama K, Hora M, Yamagishi R, Kitazawa M (2002) Effects of KMD-3213, a uroselective alpha 1A-adrenoceptor antagonist, on the tilt-induced blood pressure response in normotensive rats. Jpn J Pharmacol 90:131-137
2. Andros E, Detmar-Hanna D, Suteparuk S, Gal J, Gerber JG (1996) The effect of aging on the pharmacokinetics and pharmacodynamics of prazosin. Eur J Clin Pharmacol 50:41-46
3. Arunlakshano O, Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol 14:48-58
4. Barnes TR, McPhillips MA (1999) Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics. Br J Psychiatry Suppl 38:34-43
5. Beasley CM Jr., Hamilton SH, Crawford AM, Dellva MA, Tollefson GD, Tran PV, Blin O, Beuzen JN (1997) Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 7:125-137
6. Buckley NA, Sanders P (2000) Cardiovascular adverse effects of antipsychotic drugs. Drug Safety 23:215-228
7. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302:381-389
8. Casey DE (1996) Side effect profiles of new antipsychotic agents. J Clin Psychiatry 57(Suppl 11):40-45
9. Casey DE (1997) The relationship of pharmacology to side effects. J Clin Psychiatry 58(Suppl 10):55-62
10. Daly CJ, Deighan C, McGee A, Mennie D, Ali Z, McBride M, McGrath JC (2002) A knockout approach indicates a minor vasoconstrictor role for vascular alpha1B-adrenoceptors in mouse. Physiol Genomics 9:85-91
11. de Moura MM, dos Santos RA, Fontes MA (2005) Evidence for a functional cardiac interaction between losartan and angiotensin-(1-7) receptors revealed by orthostatic tilting test in rats. Br J Pharmacol 144:755-760
12. Docherty JR (1998) Subtypes of functional alpha1- and alpha2-adrenoceptors. Eur J Pharmacol 361:1-15
13. Eltze M (1996) In functional experiments, risperidone is selective, not for the B, but for the A subtype of alpha 1-adrenoceptors. Eur J Pharmacol 295:69-73
14. Fenger-Gron J, Mulvany MJ, Christensen KL (1995) Mesenteric blood pressure profile of conscious, freely moving rats. J Physiol 488(Pt 3):753-760
15. Gisbert R, Madrero Y, Sabino V, Noguera MA, Ivorra MD, D'Ocon P (2003) Functional characterization of alpha 1-adrenoceptor subtypes in vascular tissues using different experimental approaches: a comparative study. Br J Pharmacol 138:359-368
16. Hashimoto Y, Ohashi R, Minami K, Narita H (1999) Comparative study of TA-606, a novel angiotensin II receptor antagonist, with losartan in terms of species difference and orthostatic hypotension. Jpn J Pharmacol 81:63-72
17. Hieble JP, Kolpak DC, McCafferty GP, Ruffolo RR Jr., Testa R, Leonardi A (1999) Effects of alpha1-adrenoceptor antagonists on agonist and tilt-induced changes in blood pressure: relationships to uroselectivity. Eur J Pharmacol 373:51-62
18. Hrometz SL, Edelmann SE, McCune DF, Olges JR, Hadley RW, Perez DM, Piascik MT (1999) Expression of multiple alpha1-adrenoceptors on vascular smooth muscle: correlation with the regulation of contraction. J Pharmacol Exp Ther 290:452-463
19. Hussain MB, Marshall I (1997) Characterization of alpha1-adrenoceptor subtypes mediating contractions to phenylephrine in rat thoracic aorta, mesenteric artery and pulmonary artery. Br J Pharmacol 122:849-858
20. Ipsen M, Zhang Y, Dragsted N, Han C, Mulvany MJ (1997) The antipsychotic drug sertindole is a specific inhibitor of alpha1A-adrenoceptors in rat mesenteric small arteries. Eur J Pharmacol 336:29-35
21. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA (2002) The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 441:137-140
22. Keck PE Jr., McElroy SL (2003) Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Expert Opin Investig Drugs 12:655-662
23. Kenny BA, Chalmers DH, Philpott PC, Naylor AM (1995) Characterization of an alpha 1D-adrenoceptor mediating the contractile response of rat aorta to noradrenaline. Br J Pharmacol 115:981-986
24. Kopala LC, Day C, Dillman B, Gardner D (1998) A case of risperidone overdose in early schizophrenia: a review of potential complications. J Psychiatry Neurosci. 23:305-308
25. Kujawa K, Leurgans S, Raman R, Blasucci L, Goetz CG (2000) Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease. Arch Neurol 57:1461-1463
26. Lane RF, Blaha CD, Rivet JM (1988) Selective inhibition of mesolimbic dopamine release following chronic administration of clozapine: involvement of alpha 1-noradrenergic receptors demonstrated by in vivo voltammetry. Brain Res 460:398-401
27. Lang AE, Riley DE, Vachon L, Lataste X (1990) CQA 206-291 in Parkinson's disease: an acute single escalating dosage study. Can J Neurol Sci 17:416-419
28. Lewis DA, Lieberman JA (2000) Catching up on schizophrenia: natural history and neurobiology. Neuron 28:325-334
29. Lidow MS, Williams GV, Goldman-Rakic PS (1998) The cerebral cortex: a case for a common site of action of antipsychotics. Trends Pharmacol Sci 19:136-140
30. Lopes dF Sr., Zanella MT, Andriolo A, Ribeiro AB, Chacra AR (1988) Peripheral dopaminergic blockade for the treatment of diabetic orthostatic hypotension. Clin Pharmacol Ther 44:670-674
31. Marti D, Miquel R, Ziani K, Gisbert R, Ivorra MD, Anselmi E, Moreno L, Villagrasa V, Barettino D, D'Ocon P (2005) Correlation between mRNA levels and functional role of alpha1-adrenoceptor subtypes in arteries: evidence of alpha1L as a functional isoform of the alpha1A-adrenoceptor. Am J Physiol Heart Circ Physiol 289:H1923-H1932
32. Mulvany MJ, Halpern W (1977) Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 41:19-26
33. Piascik MT, Perez DM (2001) Alpha1-adrenergic receptors: new insights and directions. J Pharmacol Exp Ther 298:403-410
34. Poon IO, Braun U (2005) High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans. J Clin Pharm Ther 30:173-178
35. Prinssen EP, Ellenbroek BA, Cools AR (1994) Combined antagonism of adrenoceptors and dopamine and 5-HT receptors underlies the atypical profile of clozapine. Eur J Pharmacol 262:167-170
36. Richelson E, Souder T (2000) Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 68:29-39
37. Sanchez C, Kreilgaard M (2004) R-Citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram. Pharmacol Biochem Behav 77:391-398
38. Schmidt AW, Lebel LA, Howard HR Jr., Zorn SH (2001) Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 425:197-201
39. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van GP, Lesage AS, De LK, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 124:57-73
40. Sigurdardottir GR, Nilsson C, Odin P, Grabowski M (2001) Cardiovascular effects of domperidone in patients with Parkinson's disease treated with apomorphine. Acta Neurol Scand 104:92-96
41. Silver H, Kogan H, Zlotogorski D (1990) Postural hypotension in chronically medicated schizophrenics. J Clin Psychiatry 51:459-462
42. Sleight AJ, Koek W, Bigg DC (1993) Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: risperidone is selective for the alpha 1B-adrenoceptors. Eur J Pharmacol 238:407-410
43. Sramek JJ, Mack RJ, Awni W, Hourani J, Jhee SS, Barto S, Cutler NR (1997) Two rapid-dose titrations of sertindole in patients with schizophrenia. J Clin Psychopharmacol 17:419-422
44. Stam WB, Van der Graaf PH, Saxena PR (1999) Analysis of alpha 1L-adrenoceptor pharmacology in rat small mesenteric artery. Br J Pharmacol 127:661-670
45. Stanniland C, Taylor D (2000) Tolerability of atypical antipsychotics. Drug Safety 22:195-214
46. Strange PG (2001) Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev 53:119-133
47. Svensson TH (2003) Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27:1145-1158
48. Take H, Shibata K, Awaji T, Hirasawa A, Ikegaki I, Asano T, Takada T, Tsujimoto G (1998) Vascular alpha1-adrenoceptor subtype selectivity and alpha1-blocker-induced orthostatic hypotension. Jpn J Pharmacol 77:61-70
49. Testa R, Guarneri L, Angelico P, Poggesi E, Taddei C, Sironi G, Colombo D, Sulpizio AC, Naselsky DP, Hieble JP, Leonardi A (1997) Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part II. J Pharmacol Exp Ther 281:1284-1293
50. Tuunainen A, Wahlbeck K, Gilbody S (2002) Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophr Res 56:1-10
51. Wadenberg ML, Hertel P, Fernholm R, Hygge BK, Ahlenius S, Svensson TH (2000) Enhancement of antipsychotic-like effects by combined treatment with the alpha1-adrenoceptor antagonist prazosin and the dopamine D2 receptor antagonist raclopride in rats. J Neural Transm 107:1229-1238
52. Williams JB, Mallorga PJ, Jeffrey CP, Pettibone DJ, Sur C (2004) Effects of typical and atypical antipsychotics on human glycine transporters. Schizophr Res 71:103-112